Biopharma PEG Scientific Inc. is expanding its portfolio of functionalized polyethylene glycol (PEG) linkers to support research in bioconjugation, bioorthogonal chemistry, drug delivery, and related biopharmaceutical applications.

Functionalized PEG linkers are used in a range of research workflows where researchers need to connect biomolecules or other molecular components while introducing a defined spacer and reactive group. The choice of PEG length, molecular architecture, and terminal functionality can be important when developing and optimizing conjugation strategies.

Biopharma PEG’s portfolio includes azide, alkyne, DBCO, and BCN PEG derivatives, as well as PEGs functionalized with amine, thiol, NHS ester, maleimide, carboxylic acid, and other commonly used reactive groups.

The portfolio supports both copper-catalyzed and copper-free click chemistry approaches. Azide and alkyne PEGs can be used in copper-catalyzed azide–alkyne cycloaddition (CuAAC), while DBCO and BCN PEGs provide options for strain-promoted azide–alkyne cycloaddition (SPAAC).

In addition to click chemistry applications, functionalized PEG derivatives can be used in protein and peptide conjugation, molecular labeling, biomaterial research, drug delivery studies, and other bioconjugation workflows.

“We hope to provide high-purity PEG linkers that give researchers practical choices for their specific chemistry and application,” said Sonia Lee, Head of Business Development at Biopharma PEG. “Different research programs can require different PEG lengths, architectures, and functional groups, and we aim to support those requirements with both catalog and custom PEG solutions.”